|[November 23, 2012]
Research and Markets: HIV/AIDS Therapeutics Market to 2018
DUBLIN --(Business Wire)--
Research and Markets (http://www.researchandmarkets.com/research/cnk25v/hivaids)
has announced the addition of the "HIV/AIDS
Therapeutics Market to 2018 - Despite Major Patent Expiries, Increased
Uptake of Once-a-Day Fixed-dose Combination Drugs to Drive Growth"
report to their offering.
Stribild Introduction to Reinforce HIV/AIDS Revenues as Key Patents
Gilead Science's combination drug Stribild (previously known as the Quad
pill) is expected to bolster the HIV/AIDS therapeutics market as a
number of significant medications go off-patent over the next few years,
states business intelligence provider GBI Research in its latest
Forecasts from the firm's latest report indicate that the global
HIV/AIDS therapeutics market will increase in value at a Compound Annual
Growth Rate (CAGR) of 7% between the years 2011 and 2018, from $13.5
billion to $21.8 billon.
As a consequence of the on-going patent-cliff, this predicted growth
rate is less than the market experienced in previous years. Between 2004
and 2011, the market experienced a more impressive CAGR of 12.5%, but
due to the impending expiry of key medications, including Sustiva and
Reyataz (both produced by Bristol-Myers Squibb) in 2014 and 2017
respectively, a more modest increase is predicted.
However, the market is not without promise. The multi-class fixed dose
combination tablet from Gilead Sciences, Atripla, saw global revenue
increase from $2.9 billion in 2010 to $3.2 billion last year, while
potential blockbuster Stribild was approved by the US Food and Drug
Administration in August of this year and is expected to make a major
Gilead announced Stribild's initial price as $28,500, which is one-third
greater than that of Atripla, but with impressive efficacy and strong
patient compliance, GBI Research do not expect this higher cost to be a
significant barrier to widespread use.
Last year's sales figures show Gilead as being the greatest revenue
shareholder of the world's top seven markets, with 36%. With less than
half of that number, Bristol-Myers Squibb came second with 16%, while
ViiV Healthcare completed the top three with a 13% segment.
This report provides insights into the Human Immunodeficiency
Virus/Acquired Immunodeficiency Syndrome) HIV/AIDS therapeutics market
including market forecasts up to 2018.
The report is built using data and information sourced from proprietary
databases, primary and secondary research and in-house analysis by GBI
Research's team of industry experts.
- Gilead Sciences, Inc
- GlaxoSmithKline (GSK)
- Abbott Laboratories
- Johnson & Johnson (J&J)
For more information visit http://www.researchandmarkets.com/research/cnk25v/hivaids.
[ InfoTech Spotlight's Homepage ]